Here are 1-3 brief analogies to describe Profound Medical (PROF):

• An Intuitive Surgical (ISRG) for MR-guided tissue ablation.

• A Boston Scientific (BSX) or Hologic (HOLX) specializing in MRI-guided therapeutic systems.

• TULSA-PRO system: A lead product used for magnetic resonance imaging guided ablation procedures primarily for prostate disease.
• Sonalleve: A therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with bone metastases.

1. Hospitals and University Medical Centers: These are primary adopters of advanced medical technology, integrating Profound Medical's systems into departments such as urology, interventional radiology, oncology, and gynecology for various therapeutic procedures.
2. Specialized Treatment Centers and Clinics: These facilities focus on specific conditions like prostate disease, uterine fibroids, or pain management, offering targeted, minimally invasive treatment options to patients.
3. Research and Academic Institutions: These organizations may acquire Profound Medical's systems for conducting clinical trials, advancing medical research, developing new procedures, and training medical professionals.

Philips (NYSE: PHG)

Arun Menawat, Chairman and CEO

Dr. Arun Menawat joined Profound Medical as Chief Executive Officer in August 2016, having been a board member for approximately two years prior to that. He previously served as Chairman and CEO of Novadaq Technologies Inc. for 13 years, leading it from a startup to a NASDAQ-listed medical technology company with a market capitalization often exceeding one billion USD. Novadaq was later acquired by Stryker Corporation. Before Novadaq, Dr. Menawat was President of Cedara Software Corp., a company that developed an industry-first medical imaging software platform now integrated into IBM's Watson Health. He has experience guiding multiple companies through the transition from private to public funding. In 2014, he was recognized as the EY Ontario Entrepreneur of the Year in the health sciences category. Dr. Menawat holds a Ph.D. in Chemical Engineering and an Executive MBA.

Rashed Dewan, Chief Financial Officer

Rashed Dewan possesses over 20 years of finance and accounting experience within both public and private companies, with a specialized focus on the medical device sector. He has extensive experience in systems design and implementation, alongside a strong record of success in accounting, finance, sales, and operations management. Mr. Dewan is a Certified Public Accountant and holds a Bachelor of Science Degree in Accounting from the University of Southern California. He was promoted to Vice President of Finance in August 2016.

Tom Tamberrino, Chief Commercial Officer

Mr. Tom Tamberrino is a seasoned leader known for his distinguished career in sales and marketing leadership, business development, and executive management, primarily within the U.S. healthcare industry. His background includes entrepreneurial ventures and significant contributions to the medical technology sector. Before joining Profound Medical, Mr. Tamberrino served as Vice President of Sales and Marketing at Novadaq Technologies Inc., where he played a key role in establishing the company as a market leader in near-infrared fluorescence imaging and driving substantial revenue growth.

Chris Driver, VP, Product Development

Chris Driver serves as the Vice President of Product Development. Background information is not readily available in the provided search results.

Ian McLean, Vice President Of Business Development

Ian McLean holds the position of Vice President of Business Development. Background information is not readily available in the provided search results.

The key risks to Profound Medical's business revolve primarily around its financial viability and the ongoing challenges in achieving broad market adoption for its innovative medical devices amid strong competition.

1. Significant Financial Distress and Inability to Achieve Profitability

Profound Medical faces substantial financial challenges, evidenced by deeply negative operating margins (e.g., -294.83% in Q4 2025) and net margins (e.g., -273.94% in Q4 2025), indicating significant struggles in achieving profitability. The company's Altman Z-Score, a measure of financial health, has been noted to be in the "distress zone" or indicating financial distress, suggesting a potential risk of bankruptcy within the next two years. Despite some revenue growth, the company continues to experience persistent heavy losses and a large cash burn. Analysts project continued losses through 2025 and 2026, which could potentially exhaust current cash reserves, necessitating further dilution through equity offerings or additional debt. Furthermore, the company's valuation ratios, such as its P/S ratio (10.11 to 13) and P/B ratio (4.81 to 4.89), are considered high compared to historical ranges or industry averages, suggesting the stock may be overvalued despite its lack of profitability. A crucial factor for improving financial health is the need to drive higher utilization of its installed TULSA-PRO systems to reach profitability targets.

2. Slow Market Adoption and Intense Competition

Despite its innovative TULSA-PRO system receiving FDA approval in 2019, Profound Medical has struggled with limited revenue growth and unprofitability since then. The company operates in a highly competitive landscape, facing established prostate treatment modalities and similar devices from competitors like Intuitive Surgical (with its da Vinci system) and EDAP TMS S.A. (with its FocalONE platform). A challenge for TULSA-PRO is the perception in some parts of the medical community that it remains an "emerging platform," despite substantial clinical evidence supporting its efficacy. Risks also include the pace of TULSA-PRO's installed base expansion and variability in procedure volumes. The broader medtech sector faces inherent commercialization challenges, including market complexity, evolving regulations, and lengthy approval processes, all of which can impede product adoption. Additionally, there are operational scaling risks as the company aims to expand its logistics and operations, and potential disruptions could arise from new cancer treatments or tariffs.

3. Regulatory and Reimbursement Challenges

As a medical device company, Profound Medical is continuously exposed to regulatory challenges within the healthcare sector. While its TULSA-PRO and Sonalleve systems have received various clearances and approvals in major global markets, including the U.S. FDA, Health Canada, and CE Mark, the dynamic nature of medical device regulation means ongoing compliance and securing future approvals for new indications or market expansions remain a persistent risk. Furthermore, obtaining favorable and consistent reimbursement for its procedures is critical for widespread adoption and sustained revenue growth.

Two clear emerging threats for Profound Medical are:

1. Advancements in highly targeted radiation therapies for pain palliation: For the treatment of palliative pain associated with bone metastases, therapies such as Stereotactic Body Radiation Therapy (SBRT) are continuously improving in precision, efficacy, and accessibility. These advanced radiation techniques offer a powerful and often more widely available alternative to MRI-guided ablation (like Profound's Sonalleve), potentially reducing the market demand for interventional ablative procedures for this indication due to their lower barrier to adoption and established clinical workflows.
2. Evolution of effective, non-MRI guided focal therapies for prostate disease: While Profound Medical's TULSA-PRO system leverages MRI guidance for precision in prostate ablation, ongoing research and development in other focal therapy modalities (e.g., advanced ultrasound-guided High-Intensity Focused Ultrasound (HIFU) or cryoablation) aim to achieve comparable outcomes without the high capital expenditure and operational complexity associated with integrated MRI systems. If these non-MRI dependent alternatives can demonstrate equivalent efficacy, safety, and a significantly lower cost or easier adoption pathway, they could pose a substantial competitive threat to MRI-guided ablation technologies.

Profound Medical (symbol: PROF) operates in the medical device sector, focusing on magnetic resonance-guided ablation procedures. The addressable markets for its main products, TULSA-PRO and Sonalleve, are substantial across various regions.

TULSA-PRO System (Prostate Disease)

Profound Medical estimates its addressable prostate disease market for the TULSA-PRO system, particularly with the TULSA-AI Volume Reduction module, to be approximately 600,000 patients annually. Earlier company estimates suggested an annual addressable market of 200,000 cases of prostate cancer and 400,000 cases of benign prostatic hyperplasia (BPH) for TULSA-PRO, equating to a total addressable market of $4.8 billion. While the region for this specific dollar figure isn't explicitly stated, it is likely focused on major Western markets such as the U.S. The broader global prostate cancer treatment market size was an estimated USD 17.0 billion in 2024 and is projected to reach USD 31.99 billion by 2030.

Sonalleve (Uterine Fibroids and Palliative Pain Treatment)

Uterine Fibroids

For the treatment of uterine fibroids, the global uterine fibroid treatment device market was valued at USD 7 billion in 2024 and is anticipated to grow to USD 13.8 billion by 2034. North America held the largest share of this market, accounting for 42.5% in 2024. Another market analysis estimates the global uterine fibroid treatment devices market at USD 11.42 billion in 2024, with a projection to increase to approximately USD 27.53 billion by 2034. In this market, North America held a significant 62% market share in 2024.

Palliative Pain Treatment (associated with metastases in bone)

While Sonalleve specifically targets palliative pain relief associated with bone metastases, broader market data for palliative treatment or palliative care provides context. The global palliative treatment market size was valued at USD 19.8 billion in 2024 and is expected to reach USD 30.8 billion by 2035. North America's palliative treatment market was valued at USD 8 billion in 2024 and is projected to rise to USD 12 billion by 2035. Another report indicates the global palliative care market size was estimated at USD 125,707.9 million in 2023 and is projected to reach USD 243,216.4 million by 2030. Europe was identified as the largest revenue-generating market in 2023 within the global palliative care sector.

Profound Medical Corp. (NASDAQ:PROF) is poised for future revenue growth over the next 2-3 years, driven by several key initiatives and market expansions:

1. Expansion of TULSA-PRO Installed Base and Utilization: Profound Medical is focused on significantly increasing the number of TULSA-PRO system installations and enhancing their utilization. Management expects to reach approximately 120 TULSA-PRO sites by the end of 2026, up from 78 at the close of 2025. This expansion is anticipated to lead to higher patient treatment rates and a corresponding increase in high-margin recurring revenue from one-time use devices and service contracts.
2. Clinical Milestones from the CAPTAIN Trial: The imminent release of primary safety and quality of life endpoints from the completed CAPTAIN trial is a crucial catalyst. This Level 1 post-market study directly compares TULSA-PRO to robotic radical prostatectomy. Positive outcomes are expected to establish foundational clinical evidence, supporting TULSA-PRO as a new treatment paradigm for prostate disease and driving wider adoption among clinicians and patients.
3. Global Commercial Expansion into New Markets: The company is actively executing a global commercial strategy to broaden its market reach. This includes regaining exclusive distribution rights for TULSA-PRO in Canada and securing new distribution agreements in key international markets such as Saudi Arabia, Australia, and New Zealand, thereby expanding its geographic footprint and potential customer base.
4. Launch and Adoption of TULSA-AI Volume Reduction Module: The introduction of the TULSA-AI Volume Reduction module is expected to significantly expand TULSA-PRO's addressable market. By offering reduced procedure times for benign prostatic hyperplasia (BPH), this module is projected to potentially triple the addressable prostate disease market to approximately 600,000 patients annually.
5. Growth of Sonalleve and Exploration of New Indications: While TULSA-PRO remains a primary focus, the Sonalleve therapeutic platform is gaining increasing commercial interest, particularly outside the United States, for applications like uterine fibroids and palliative pain relief. Profound Medical is also actively exploring additional potential treatment markets for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy, which could unlock new revenue streams.

Capital Allocation Decisions for Profound Medical (PROF)

Share Issuance

• In December 2025, Profound Medical completed a registered direct offering in the United States, raising approximately $36.0 million in gross proceeds, and an upsized private placement in Canada, raising up to US$6.45 million.
• For the year ended December 31, 2025, the issuance of common shares provided approximately $42.4 million in cash from financing activities.
• As of March 5, 2026, Profound Medical had 36,293,640 common shares issued and outstanding.

Inbound Investments

• In December 2025, Profound Medical secured approximately $42.45 million through equity financings, including a $36.0 million registered direct offering in the U.S. and a $6.45 million private placement in Canada.
• These equity investments were structured without warrant coverage and were led by healthcare-dedicated investors, including existing shareholders.

Capital Expenditures

• In the last 12 months, as of December 31, 2025, capital expenditures amounted to approximately $176,000.
• For the year ended December 31, 2025, the purchase of property and equipment was approximately $176,000 and the purchase of intangible assets was approximately $66,000.
• Net proceeds from recent offerings are intended to be used for expansion of sales and marketing, working capital, research and development, strategic transactions, and general corporate purposes.